Edition:
United Kingdom

Aclaris Therapeutics Inc (ACRS.OQ)

ACRS.OQ on NASDAQ Stock Exchange Global Select Market

19.12USD
22 May 2018
Change (% chg)

$0.03 (+0.16%)
Prev Close
$19.09
Open
$19.04
Day's High
$19.23
Day's Low
$18.99
Volume
8,027
Avg. Vol
110,060
52-wk High
$30.06
52-wk Low
$16.24

Select another date:

Tue, May 8 2018

BRIEF-Aclaris Therapeutics Q1 Loss Per Share $0.98

* ACLARIS THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS

BRIEF-Aclaris Therapeutics Announces Availability Of Eskata In The U.S.

* ACLARIS THERAPEUTICS ANNOUNCES AVAILABILITY OF ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W)

BRIEF-Aclaris Therapeutics Names Bryan Reasons Director And Chairman, Audit Committee

* ACLARIS THERAPEUTICS ANNOUNCES APPOINTMENT OF BRYAN REASONS AS A DIRECTOR AND CHAIRMAN OF THE AUDIT COMMITTEE Source text for Eikon: Further company coverage:

BRIEF-Aclaris Says Primary, Secondary, And Exploratory Endpoints Of Phase 2 Trial of A-101 45% Met

* ACLARIS THERAPEUTICS ANNOUNCES POSITIVE UPDATE ON PHASE 2 RESULTS AFTER A 3-MONTH FOLLOW-UP OF A-101 45% TOPICAL SOLUTION FOR POTENTIAL TREATMENT OF COMMON WARTS

BRIEF-Aclaris Therapeutics Q4 Revenue $1.0 Mln

* ACLARIS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL AND COMMERCIAL DEVELOPMENTS

BRIEF-Aclaris Therapeutics Issues U.S. Patent Covering JAK Inhibitor For Treating Hair Loss Disorders

* ACLARIS THERAPEUTICS ANNOUNCES ISSUANCE OF U.S. PATENT COVERING A JAK INHIBITOR FOR TREATING HAIR LOSS DISORDERS Source text for Eikon: Further company coverage:

BRIEF-Aclaris Therapeutics Signs Agreement With James Alexander Corp

* ACLARIS THERAPEUTICS SAYS ON JAN 24, CO ENTERED INTO COMMERCIAL SUPPLY MANUFACTURING SERVICES AGREEMENT WITH JAMES ALEXANDER CORP - SEC FILING

BRIEF-Aclaris Therapeutics' A-101 45% Topical Solution Meets Primary, All Secondary Endpoints In Two Phase 2 Clinical Trials For Common Warts

* ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS

Aclaris's drug to treat common skin growth gets FDA nod

Aclaris Therapeutics Inc's drug to treat a common kind of skin growth called seborrheic keratoses received approval from the U.S. Food and Drug Administration, the company said on Friday.

UPDATE 2-Aclaris's drug to treat common skin growth gets FDA nod

Dec 15 Aclaris Therapeutics Inc's drug to treat a common kind of skin growth called seborrheic keratoses received approval from the U.S. Food and Drug Administration, the company said on Friday.

Select another date: